Chromadex Corp (CDXC) Stock Rating Lowered by Zacks Investment Research
Chromadex Corp (OTCMKTS:CDXC) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.
According to Zacks, “ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex’s core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company’s main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. “
CDXC has been the subject of several other research reports. HC Wainwright set a $6.00 price target on Chromadex Corp and gave the company a “buy” rating in a report on Monday, February 27th. Rodman & Renshaw began coverage on Chromadex Corp in a report on Tuesday, January 3rd. They issued a “buy” rating and a $6.00 price target for the company.
Chromadex Corp (OTCMKTS:CDXC) traded down 3.19% during mid-day trading on Monday, hitting $2.73. 164,891 shares of the company were exchanged. The stock’s market cap is $103.48 million. The firm has a 50 day moving average price of $2.78 and a 200 day moving average price of $2.86. Chromadex Corp has a 12 month low of $2.25 and a 12 month high of $6.18.
Your IP Address:
Chromadex Corp Company Profile
Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chromadex Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex Corp and related companies with MarketBeat.com's FREE daily email newsletter.